{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:59:07Z","timestamp":1772812747521,"version":"3.50.1"},"reference-count":107,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.beem.2022.101701","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T12:04:37Z","timestamp":1662725077000},"page":"101701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Innovative tumour targeting therapeutics in Cushing's disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Vivian","family":"von Selzam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marily","family":"Theodoropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101701_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-15-0807","article-title":"Limited value of cabergoline in Cushing\u2019s disease: a prospective study of a 6-week treatment in 20 patients","volume":"174","author":"Burman","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40618-016-0462-4","article-title":"Role of \u201cold\u201d pharmacological agents in the treatment of Cushing\u2019s syndrome","volume":"39","author":"Ambrogio","year":"2016","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101701_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ecl.2018.01.006","article-title":"Medical therapy for cushing\u2019s syndrome in the twenty-first century","volume":"47","author":"Tritos","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.beem.2022.101701_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4158\/EP.13.3.296","article-title":"Cushing\u2019s disease and pregnancy: case report and literature review","volume":"13","author":"Yawar","year":"2007","journal-title":"Endocr Pract"},{"key":"10.1016\/j.beem.2022.101701_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.14310\/horm.2002.1685","article-title":"Cabergoline treatment for recurrent Cushing\u2019s disease during pregnancy","volume":"15","author":"Nakhleh","year":"2016","journal-title":"Hormones (Basel)"},{"key":"10.1016\/j.beem.2022.101701_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217855","article-title":"Use of cabergoline for the management of persistent Cushing\u2019s disease in pregnancy","volume":"2017","author":"Sek","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.beem.2022.101701_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib12","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas","volume":"91","author":"Batista","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000327429","article-title":"Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing\u2019s disease","volume":"94","author":"Castillo","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2022.101701_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib15","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101701_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A\u00a012-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101701_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","article-title":"Extended treatment of Cushing\u2019s disease with pasireotide: results from a 2-year, Phase II study","volume":"17","author":"Boscaro","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","article-title":"Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial","volume":"18","author":"Schopohl","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_bib20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11102-017-0853-3","article-title":"A\u00a0prospective longitudinal study of Pasireotide in Nelson\u2019s syndrome","volume":"21","author":"Daniel","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_bib22","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1210\/jc.2013-1497","article-title":"Sustained improvements in plasma ACTH and clinical status in a patient with Nelson\u2019s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog","volume":"98","author":"Katznelson","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40842-020-00110-7","article-title":"Rapid response of Nelson\u2019s syndrome to pasireotide in radiotherapy-naive patient","volume":"6","author":"He","year":"2020","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_bib25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","article-title":"Retinoic acid prevents experimental Cushing syndrome","volume":"108","author":"P\u00e1ez-Pereda","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2022.101701_bib26","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","article-title":"Retinoic acid as a novel medical therapy for Cushing\u2019s disease in dogs","volume":"147","author":"Castillo","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2022.101701_bib27","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","article-title":"Potential role for retinoic acid in patients with Cushing\u2019s disease","volume":"97","author":"Pecori Giraldi","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8173182","article-title":"The role of isotretinoin therapy for cushing\u2019s disease: results of a prospective study","volume":"2016","author":"Vilar","year":"2016","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib29","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1210\/en.2013-1820","article-title":"Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing\u2019s disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation","volume":"155","author":"Occhi","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2022.101701_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-020-00284-7","article-title":"Bexarotene combined with lapatinib for the treatment of Cushing\u2019s disease: evidence based on drug repositioning and experimental confirmation","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.beem.2022.101701_bib31","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/jcmm.16074","article-title":"Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT-20 cells","volume":"25","author":"Xia","year":"2021","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.beem.2022.101701_bib32","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nm784","article-title":"Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas","volume":"8","author":"Heaney","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.beem.2022.101701_bib33","first-page":"Rc8","article-title":"Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing\u2019s disease","volume":"27","author":"Cannav\u00f2","year":"2004","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101701_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","article-title":"Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing\u2019s disease","volume":"151","author":"Ambrosi","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib35","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","article-title":"Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing\u2019s disease","volume":"90","author":"Suri","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib36","first-page":"430","article-title":"No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson\u2019s syndrome and Cushing\u2019s disease in\u00a0vitro and in\u00a0vivo","volume":"28","author":"Kreutzer","year":"2009","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.beem.2022.101701_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/eje.1.01994","article-title":"Rosiglitazone for prevention or adjuvant treatment of Nelson\u2019s syndrome after bilateral adrenalectomy","volume":"153","author":"Andreassen","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2265.2006.02501.x","article-title":"The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson\u2019s syndrome","volume":"64","author":"Mullan","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib39","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1210\/jc.2006-2005","article-title":"Ineffectiveness of rosiglitazone therapy in Nelson\u2019s syndrome","volume":"92","author":"Munir","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib40","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1073\/pnas.1306182110","article-title":"Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease","volume":"110","author":"Du","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2022.101701_bib41","doi-asserted-by":"crossref","first-page":"13437","DOI":"10.1074\/jbc.273.22.13437","article-title":"Negative feedback control of the retinoid-retinoic acid\/retinoid X receptor pathway by the human TR4 orphan receptor, a member of the steroid receptor superfamily","volume":"273","author":"Lee","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2022.101701_bib42","doi-asserted-by":"crossref","first-page":"R279","DOI":"10.1530\/ERC-13-0529","article-title":"Differential roles of PPAR\u03b3 vs TR4 in prostate cancer and metabolic diseases","volume":"21","author":"Liu","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101701_bib43","first-page":"306","article-title":"Steroid receptor interactions with heat shock protein and immunophilin chaperones","volume":"18","author":"Pratt","year":"1997","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2022.101701_bib44","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1073\/pnas.96.4.1439","article-title":"The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter","volume":"96","author":"Kang","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2022.101701_bib45","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1126\/science.1073051","article-title":"Disassembly of transcriptional regulatory complexes by molecular chaperones","volume":"296","author":"Freeman","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.beem.2022.101701_bib46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3776","article-title":"A\u00a0C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease","volume":"21","author":"Riebold","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.beem.2022.101701_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beem.2022.101701_bib48","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2165\/00003495-200161140-00003","article-title":"The use of silymarin in the treatment of liver diseases","volume":"61","author":"Saller","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2022.101701_bib49","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1111\/bph.12844","article-title":"Targeting the histone orthography of cancer: drugs for writers, erasers and readers","volume":"172","author":"Sim\u00f3-Riudalbas","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.beem.2022.101701_bib50","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1507\/endocrj.EJ15-0369","article-title":"Inhibitory effects of trichostatin A on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells","volume":"62","author":"Nakada","year":"2015","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2022.101701_bib51","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1210\/jc.2017-00464","article-title":"Histone deacetylase inhibitor SAHA is a promising treatment of cushing disease","volume":"102","author":"Lu","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib52","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1210\/clinem\/dgaa699","article-title":"Targeting corticotroph HDAC and PI3-kinase in cushing disease","volume":"106","author":"Zhang","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib53","doi-asserted-by":"crossref","DOI":"10.1507\/endocrj.EJ21-0778","article-title":"Effects of tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells","author":"Hagiwara","year":"2022","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2022.101701_bib54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.beem.2022.101701_bib55","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40618-021-01735-w","article-title":"PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells","volume":"45","author":"Oliveira","year":"2022","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101701_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/ERC-19-0448","article-title":"Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells","volume":"27","author":"Lines","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101701_bib57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1677\/joe.1.05616","article-title":"Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells","volume":"183","author":"Theodoropoulou","year":"2004","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib58","doi-asserted-by":"crossref","first-page":"M73","DOI":"10.1530\/EJE-15-0320","article-title":"Decoding the genetic basis of Cushing\u2019s disease: USP8 in the spotlight","volume":"173","author":"Theodoropoulou","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib59","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2022.101701_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2022.101701_bib61","doi-asserted-by":"crossref","first-page":"e13148","DOI":"10.1111\/jne.13148","article-title":"Genetics of Cushing\u2019s disease","author":"Simon","year":"2022","journal-title":"J\u00a0Neuroendocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib62","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14740338.5.3.469","article-title":"Gefitinib: an adverse effects profile","volume":"5","author":"Cersosimo","year":"2006","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.beem.2022.101701_bib63","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res"},{"key":"10.1016\/j.beem.2022.101701_bib64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1507\/endocrj.EJ18-0491","article-title":"Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells","volume":"66","author":"Asari","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2022.101701_bib65","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1038\/s41467-018-05275-5","article-title":"Identification of recurrent USP48 and BRAF mutations in Cushing\u2019s disease","volume":"9","author":"Chen","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2022.101701_bib66","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/neuonc\/noz109","article-title":"Driver mutations in USP8 wild-type Cushing\u2019s disease","volume":"21","author":"Sbiera","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.beem.2022.101701_bib67","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s12020-021-02903-x","article-title":"USP8, USP48, and BRAF mutations differ in their genotype-phenotype correlation in Asian Indian patients with Cushing\u2019s disease","volume":"75","author":"Abraham","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101701_bib68","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","article-title":"Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5","volume":"243","author":"Meijer","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.beem.2022.101701_bib69","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/eje.0.143r001","article-title":"Cyclin D and cyclin E expression in normal and adenomatous pituitary","volume":"143","author":"Jordan","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib70","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/me.2010-0091","article-title":"Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis","volume":"24","author":"Roussel-Gervais","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib71","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1210\/jc.2015-1606","article-title":"Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for cushing disease","volume":"100","author":"Liu","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib72","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1073\/pnas.1018091108","article-title":"Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor","volume":"108","author":"Liu","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2022.101701_bib73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1677\/JOE-08-0011","article-title":"Interferon-gamma inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1\/nuclear factor-kappa B inhibitory signaling pathway","volume":"199","author":"Labeur","year":"2008","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib74","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1677\/ERC-09-0129","article-title":"Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in\u00a0vitro and in\u00a0vivo","volume":"16","author":"Schaaf","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101701_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/38a101d6-a1f2-4a74-ab63-bc5c61e5f62b","article-title":"Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing\u2019s disease","volume":"5","author":"Bangaru","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2022.101701_bib76","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.biopha.2017.08.127","article-title":"Triptolide suppresses growth and hormone secretion in murine pituitary corticotroph tumor cells via NF-kappaB signaling pathway","volume":"95","author":"Li","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.beem.2022.101701_bib77","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.4103\/0366-6999.189047","article-title":"Inhibition of ubiquitin-specific peptidase 8 suppresses adrenocorticotropic hormone production and tumorous corticotroph cell growth in AtT20 cells","volume":"129","author":"Jian","year":"2016","journal-title":"Chinese Med J"},{"key":"10.1016\/j.beem.2022.101701_bib78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1507\/endocrj.EJ19-0239","article-title":"Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation","volume":"67","author":"Kageyama","year":"2020","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2022.101701_bib79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1530\/ERC-21-0093","article-title":"USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs","volume":"28","author":"Treppiedi","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2022.101701_bib80","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib81","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1210\/jcem.83.12.5300","article-title":"The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors","volume":"83","author":"Kaltsas","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib82","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1100\/tsw.2010.210","article-title":"Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing\u2019s disease\u2013report of a case and literature review","volume":"10","author":"Curt\u00f2","year":"2010","journal-title":"Sci World J"},{"key":"10.1016\/j.beem.2022.101701_bib83","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11102-010-0264-1","article-title":"Temozolomide for corticotroph pituitary adenomas refractory to standard therapy","volume":"14","author":"Dillard","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_bib84","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11102-011-0363-7","article-title":"Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature","volume":"15","author":"Annamalai","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_bib85","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib86","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz211","article-title":"Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-A German survey","volume":"105","author":"Elbelt","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib87","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0030-1253419","article-title":"SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases","volume":"118","author":"Bode","year":"2010","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2022.101701_bib88","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11060-014-1702-0","article-title":"Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center","volume":"122","author":"Ceccato","year":"2015","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.beem.2022.101701_bib89","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","article-title":"Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas","volume":"126","author":"Losa","year":"2016","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.beem.2022.101701_bib90","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11102-016-0755-9","article-title":"Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors","volume":"19","author":"Greenman","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_bib91","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib92","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11102-009-0211-1","article-title":"Temozolomide (Temodar\u00ae) and capecitabine (Xeloda\u00ae) treatment of an aggressive corticotroph pituitary tumor","volume":"14","author":"Thearle","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_sref93","doi-asserted-by":"crossref","first-page":"E447","DOI":"10.1227\/NEU.0000000000000251","article-title":"High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series","volume":"74","author":"Zacharia","year":"2014","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2022.101701_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.731631","article-title":"Aggressive pituitary macroadenoma treated with capecitabine and temozolomide chemotherapy combination in a patient with nelson\u2019s syndrome: a case report","volume":"12","author":"Mirallas","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13000-017-0624-5","article-title":"Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease","volume":"12","author":"Joehlin-Price","year":"2017","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.beem.2022.101701_bib96","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12022-020-09647-w","article-title":"Effects of CAPTEM (capecitabine and temozolomide) on a corticotroph carcinoma and an aggressive corticotroph tumor","volume":"32","author":"Nakano-Tateno","year":"2021","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2022.101701_bib97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/cns-2016-0011","article-title":"Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy","volume":"5","author":"Donovan","year":"2016","journal-title":"CNS Oncology"},{"key":"10.1016\/j.beem.2022.101701_bib98","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","article-title":"New targeted therapies in pituitary carcinoma resistant to temozolomide","volume":"15","author":"Jouanneau","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101701_bib99","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","article-title":"An Institutional experience of tumor progression to pituitary carcinoma in a 15-year cohort of 1055 consecutive pituitary neuroendocrine tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2022.101701_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020308","article-title":"Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the Literature-\"Are we there yet?\"","volume":"12","author":"Lamb","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2022.101701_bib101","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101701_bib102","first-page":"10","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","author":"Duhamel","year":"2020","journal-title":"J\u00a0Personalized Med"},{"key":"10.1016\/j.beem.2022.101701_bib103","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?","volume":"184","author":"Sol","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101701_bib104","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"J\u00a0Endocrine Soc"},{"key":"10.1016\/j.beem.2022.101701_bib105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.beem.2022.101701_bib106","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"Caccese","year":"2020","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.beem.2022.101701_bib107","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:59:13Z","timestamp":1761497953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521690X22000884"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101701","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative tumour targeting therapeutics in Cushing's disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101701"}}